Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
Terminated · Phase 1, Phase 2 · NCT03660930
Conditions: Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
At a glance
- Research payments reported, 2025
- $170,087
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 19
About the trial
- Sponsor
- University of Washington (with Aadi Bioscience, Inc.)
- Tested
- Sirolimus Albumin-bound Nanoparticles (drug), Pazopanib hydrochloride (drug)
- Dates
- Started 2019-04-01; completion 2024-07-31
- Results posted
- Yes
This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nab-sirolimus and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
From ClinicalTrials.gov, last updated 2025-04-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aadi Bioscience, Inc. reported $170,087 in research payments for this study in 2025 (2 payments).
Products named: Fyarro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.